A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Poly ICLC (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacodynamics
- 20 Jun 2018 Planned End Date changed from 31 Oct 2022 to 31 May 2023.
- 20 Jun 2018 Planned primary completion date changed from 30 Nov 2019 to 30 Jun 2020.
- 20 Jun 2018 Planned initiation date changed from 31 May 2018 to 31 Dec 2018.